ClinicalTrials.gg
CompletedNCT04856774Updated Jun 27, 2024

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

A Phase 1/2 interventional study of SHR-1701;BP102 in Advanced Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed solid that is or unresectable for which standard curative or palliative measures do not exist or are no longer effective (phase Ib)
  2. Histologically or cytologically confirmed metastatic or locally advanced solid tumors of the selected indications. (Phase II).
  3. . exceeds 12 weeeks;
  4. The Eastern Cancer Cooperative Group () has a performance score of 0 or 1;
  5. Normal organ and marrow function;

Exclusion criteria

Exclusion Criteria:

  1. Has known active central nervous system (CNS) . Subjects with previously treated may participate provided they are stable.
  2. A history of (HIV) infection is known, or has an active disease.
  3. History of interstitial lung disease or pneumonia requiring oral or intravenous .
  4. Has moderate or severe cardiovascular disease;
  5. Active (hepatitis B) or (Hepatitis C virus)-infected subjects;
  6. Any other within 5 years except for those with negligible risk of metastasis or death.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    SHR -1701 + BP102

    Drug: SHR-1701;BP102

Interventions

  • DrugSHR-1701;BP102

    Drug: SHR-1701 IV infusion Drug: BP102 IV infusion Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined.

06

What researchers measure

Primary outcomes

  1. recommended phase 2 dose (Phase Ib)

    Time frame: At the end of Cycle 2 (each cycle is 21 days)

  2. Objective response rate (ORR)

    Time frame: 2 years

Secondary outcomes

  1. Dose Limiting Toxicity (DLT) (Phase 1b)

    Time frame: At the end of Cycle 2 (each cycle is 21 days)

  2. Number of participants with treatment emergent adverse events (TEAEs)

    Time frame: For each participant, from the first dose till 90 days after the last dose

  3. Number of participants with treatment emergent serious adverse events (SAEs)

    Time frame: For each participant, from the first dose till 90 days after the last dose

  4. ORR

    Time frame: 2 years

  5. Duration of response (DOR)

    Time frame: 2 years

  6. Disease control rate (DCR)

    Time frame: 2 years

  7. Time to response(TTR)

    Time frame: 2 years

  8. Progression-free survival (PFS)

    Time frame: 2 years

  9. Overall survival (OS)

    Time frame: 2 years

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangzhou 510060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Mar 2024, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Apr 23, 2021
StartActual
Jun 1, 2021
Primary completionActual
Mar 30, 2024
CompletionActual
Mar 30, 2024
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04856774
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
Jun 1, 2021
Primary completion
Mar 30, 2024
Completion
Mar 30, 2024
Last update
Jun 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion